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Abstract
Purpose—To examine predictors of ammonia exposure and hyperammonemic crises (HAC) in 
patients with urea cycle disorders (UCDs).
Methods—The relationships between fasting ammonia, daily ammonia exposure, and HACs 
were analyzed in >100 UCD patients.
Results—Fasting ammonia correlated strongly with daily ammonia exposure (r=0.764, p<0.001). 
For patients with fasting ammonia levels <0.5 ULN, 0.5 to <1.0 ULN, and ≥1.0 ULN, the 
probability of a normal average daily ammonia value was 87%, 60%, and 39%, respectively, and 
10.3%, 14.1%, and 37.0% of these patients experienced ≥1 HAC over 12 months. Time to first 
HAC was shorter (p=0.008) and relative risk (4.5×; p=0.011) and rate (~5×, p=0.006) of HACs 
higher in patients with fasting ammonia ≥1.0 ULN vs. <0.5ULN; relative risk was even greater 
(20×; p=0.009) in patients ≥6 years. A 10 or 25 μmol/L increase in ammonia exposure increased 
the relative risk of a HAC by 50% and >200% (p<0.0001), respectively. The relationship between 
ammonia and HAC risk appeared independent of treatment, age, UCD subtype, dietary protein 
intake, or blood urea nitrogen. Fasting glutamine correlated weakly with AUC0-24 and was not a 
significant predictor of HACs.
Conclusions—Fasting ammonia correlates strongly and positively with daily ammonia exposure 
and with the risk and rate of HACs, suggesting that UCD patients may benefit from tight ammonia 
control.
Keywords
glycerol phenylbutyrate; hyperammonemia; RAVICTI; sodium phenylbutyrate
INTRODUCTION
Urea cycle disorders (UCDs) are inborn errors of metabolism involving deficiencies of 
enzymes required for ureagenesis. They are manifested by acute and chronic 
hyperammonemia and medical management is aimed at reducing ammonia levels through 
the restriction of protein intake and the use of alternate pathway drugs to enhance waste 
nitrogen excretion. Current UCD treatment guidelines indicate that ammonia should be kept 
within normal limits, but otherwise provide limited guidance on the specific timing of blood 
draws or target levels.1
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Glycerol phenylbutyrate (GPB, HPN-100, RAVICTI®; Hyperion Therapeutics, Inc., 
Brisbane, CA) is a sodium- and sugar-free ammonia-lowering agent that was approved in the 
United States in 2013 for UCD patients ≥ 2 years of age who cannot be managed by dietary 
protein restriction and/or amino acid supplementation alone. The GPB clinical trials 
compared 24-hour ammonia levels during short-term steady-state dosing with GPB or 
sodium phenylbutyrate (NaPBA) among 80 UCD patients ages 2 months to over 70 years 
and studied longer-term outcomes, including hyperammonemic crises (HACs), among 100 
UCD patients, including 49 pediatric patients, treated with GPB for up to 1 year.
The present report has taken advantage of over 1000 prospectively collected timed blood 
samples to analyze correlates of daily ammonia exposure, assessed as 24-hour area under the 
curve, as well as the utility of ammonia and glutamine as predictors of HACs.
METHODS
Clinical Studies
Data from four short-term switchover (SO) studies and three 12-month safety extension (SE) 
studies in adult and pediatric UCD patients were included in the analyses; all have been 
previously described. Protocols UP1204-003, HPN-100-005SO, and HPN-100-012SO were 
short-term, open-label, fixed sequence SO studies that evaluated ammonia control during 
equivalent dosing of GPB versus NaPBA.2-4 Study HPN-100-006 was a pivotal, randomized, 
double-blind, active-controlled, crossover study that established non-inferiority of GPB to 
NaPBA as assessed by venous ammonia.5 Most patients completing these protocols plus 
additional patients (a total of 100 of whom 49 were pediatric) were enrolled into safety 
extension studies and received GPB for 12 months.5-7
All protocols and informed consents were reviewed and approved by the Investigational 
Review Board of each participating institution prior to initiation. Eligible subjects had a 
confirmed or clinically suspected UCD and had been receiving NaPBA prior to enrollment. 
In all studies, patients received GPB three times daily (or more frequently in small children 
to match their prior NaPBA schedule) at a daily dose equivalent to their previously 
prescribed NaPBA dose.
Ammonia and Glutamine Measurements
During the crossover studies, serial venous blood samples for ammonia analyses were 
collected over 24 hours after the patient had received 1-2 weeks of dosing (steady state) with 
either NaPBA or GPB. Samples for glutamine and ammonia were collected after overnight 
[≥ 4-6 hours] fasting and prior to breakfast and the first daily drug dose; additional ammonia 
samples were collected at 8, 12, and 24 hours post-dose for pediatric patients; and 
approximately every 4 hours for adults. During the 12-month studies, blood samples for 
ammonia and glutamine analyses were collected monthly and information on HACs was 
recorded.
Baseline ammonia was defined as the screening or month 0 value when the patient was on 
NaPBA prior to receiving GPB. An HAC was defined as compatible clinical symptoms 
associated with one or more ammonia levels ≥ 100 μmol/L. Ammonia and HAC data were 
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also collected retrospectively for up to 12 months prior to enrollment in each study while 
patients were receiving NaPBA. Ammonia and glutamine concentrations were measured by 
an accredited hospital laboratory at each study site and ammonia values were normalized to 
a standard range of 9 to 35 μmol/L.
Statistical Analyses
Short-term Studies—Fasting ammonia levels were determined from the pre-dose and 24-
hour time points for steady-state measurements and maximum levels (Cmax) represented the 
highest levels determined during the 24 hour period. Ammonia 24-hour area under the 
concentration versus time curve from time 0 (pre-dose) to 24 hours (AUC0-24) was 
calculated using the linear trapezoid rule and average daily ammonia was calculated as 
AUC0-24 divided by time. The relationship between fasting ammonia and AUC0-24 was 
analyzed using logistic regression. Potential covariates examined included age, weight, drug 
type, and total daily dietary protein intake. Prediction intervals were calculated using 
standard least-squares methods and bootstrap methods.8 Bootstrap intervals are less 
dependent on the observed data than standard intervals, and therefore provide a more 
credible predication interval.
Fasting ammonia values were also divided into categories (< 0.5, 0.5 - < 1.0, and ≥ 1.0) 
relative to the upper limit of normal (ULN). The probability that a patient whose fasting 
ammonia falls within a given category would have normal total daily ammonia exposure was 
modeled using Generalized Estimating Equations (GEE) assuming an exchangeable 
correlation structure and a logit link function. Confidence limits around the outcome 
probabilities were computed using the bootstrap method.8
12-Month Studies—The time to first HAC was determined by Kaplan-Meier analysis9 for 
the entire population, by age group, dichotomous age group, gender and baseline ammonia 
ULN categories. Survival distributions between covariate values were computed using a log-
rank test.10 Cox regression models were used to quantify the relative risk of time to first 
HAC.
The relationship between total ammonia exposure over time and the risk of HAC occurrence 
was explored by calculating time normalized area under the curve (TNAUC12months) for 
ammonia for patients with and without an HAC during the 12-month treatment with GPB. 
The AUC for ammonia, measured monthly, was calculated for each patient using the 
trapezoid rule over the course of the 12 -month study. TNAUCxmonth was calculated by 
dividing AUC by the final study month of an ammonia assessment.
For the cumulative rate of HAC over 12 months, a negative binomial regression was 
performed with a flexible scale parameter to account for overdispersion of the HAC count 
data11 with an offset to account for varying time in the study between patients. A 
multivariable negative binomial regression of HAC rate was also developed to adjust for 
potential confounders.
A linear mixed regression model was used for the analysis of admission, peak, and discharge 
ammonia levels by patient characteristics. Log-transformed values were used for peak and 
Lee et al. Page 5
Genet Med. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
discharge ammonia levels values and the model controlled for clustering of outcomes for 
patients who had more than one HAC.12 A GEE logistic regression model was used to assess 
the association between the duration of HAC and baseline ammonia values.13 Spearman 
correlations were used to assess the relationship between baseline ammonia and glutamine 
levels.
RESULTS
The analyses included over 1000 ammonia results from 114 UCD patients, including 100 
(51 adult, 49 pediatric) in the 12-month dosing protocols. Except for fasting ammonia, 
baseline characteristics (age, gender, UCD subtype) were similar across baseline ammonia 
ULN categories, although there was a slightly higher proportion of patients aged 6 to 11 
years in the 0.5 to < 1.0 ULN group than in the other two groups and mean baseline 
glutamine values were slightly higher in the ≥ 1.0 ULN group than in the other ULN groups 
(Table 1).
Short-Term Studies
Blood ammonia levels exhibited considerable fluctuation over 24 hours; fasting ammonia 
values from morning blood draws exhibited the least variability (Figure S1). There was a 
strongly positive and statistically significant relationship between fasting ammonia and 
AUC0-24 (r = 0.764; p < 0.0001) (Figure 1). There was no discernable difference in the 
relationships observed with NaPBA and GPB treatment, so data for both drugs were 
combined. None of the potential covariates examined (e.g. age, weight, gender and dietary 
protein) had a clinically or statistically significant impact on the model and these covariates 
were not included in the final model.
When AUC and Cmax outcomes were modeled using ordered ULN categories, patients with 
a fasting ammonia < 0.5 ULN had a greater likelihood of having a normal average daily 
ammonia value than patients with a fasting ammonia in other categories (insert in Figure 1).
12-Month Studies
Ammonia—Ammonia levels during up to 12 months of dosing were strongly related to 
baseline levels as categorized in relation to the ULN. Patients whose baseline ammonia was 
< 0.5 ULN had mean monthly ammonia levels < 35 μmol/L throughout the study and their 
ammonia values showed less variability than did those among patients in the higher baseline 
ammonia categories (Figure 2, top panel). In the ammonia ≥ 1.0 ULN category, mean fasting 
ammonia decreased towards the normal range after approximately 3 months of GPB 
treatment (Figure 2, top panel).
Thirty patients (30%) experienced a total of 54 HACs in the 12 months prior to starting GPB 
treatment and 19 patients (19%) experienced a total of 27 HACs during 12 months of GPB 
treatment (Table 1). The proportion of patients experiencing an HAC increased in relation to 
baseline ammonia ULN categories (p = 0.0236) and was slightly higher for pediatric than for 
adult patients. Gender and UCD subtype had no effect on the rate of HAC. Mean (SD) 
baseline fasting ammonia in patients with a HAC was 41.8 (23.7) μmol/L as compared to 
25.7 (17.8) μmol/L in patients with no HAC (p = 0.0023).
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The time to first HAC was significantly shorter (p = 0.0077) and the risk of HAC higher 
(4.5× p = 0.011) in patients whose baseline ammonia was ≥ 1.0 ULN as compared with 
patients whose baseline ammonia was < 0.5 ULN (Figure 2). After adjusting for age, gender, 
and race, patients with one or more baseline ammonia values ≥ 1.0 ULN had approximately 
5.5x the risk of having at least one HAC than patients with baseline ammonia < 0.5 ULN (p 
= 0.005). When patients < 6 years old at baseline (who eat more frequently and for whom 
measurement of fasting ammonia is problematic) were excluded from the analysis, those 
with baseline ammonia values ≥ 1.0 ULN had an approximately 20x increase in risk of 
having an HAC than patients with baseline ammonia < 0.5 ULN (p = 0.009).
The median time in the study was 361 days. The overall rate of HACs was 0.288 per patient 
per year and the rate was significantly higher among patients with baseline ammonia ≥ 1.0 
ULN than for those with baseline ammonia < 0.5 ULN (0.711 vs. 0.135/patient/year; p = 
0.0057). Total ammonia exposure calculated as time normalized area under the curve during 
12 months of GPB dosing (TNAUC12month) was significantly lower in patients who did not 
experience an HAC (23.6 vs 35.0 μmol/L; p=0.0006). The relative risk of experiencing an 
HAC increased by about 50% and 270%, respectively, for every 10 and 25 μmol/L increase 
in ammonia exposure (p<0.0001) (Figure S3).
The proportion of patients with baseline ammonia levels within each ULN category varied 
considerably among study sites (Figure 3, top panel), which were therefore grouped into 
three categories based on the percentage of patients enrolled whose baseline fasting 
ammonia was < 0.5 of the ULN at baseline: Group 1 (6 study sites; 33 patients, of whom 
>50% had baseline ammonia levels < 0.5 ULN); Group 2 (3 study sites; 29 patients, of 
whom 25%-50% had baseline ammonia levels < 0.5 ULN); and Group 3 (11 sites; 38 
patients, of whom < 25% had baseline ammonia < 0.5 ULN) (Figure 3, bottom panel and 
Table S1). The proportion of patients who experienced an HAC was lowest (12%) among 
Group 1 sites and increased progressively to 21% and 24% in Group 2 and 3 sites (Figure 3, 
bottom panel). Although the mean age of patients in group 3 was lower compared to group 1 
(14.7 vs 24.5 yrs), other markers of disease severity including the proportion of females with 
OTC deficiency and restriction of dietary protein were similar among the groups.
During the 12 month GPB dosing protocols, HACs were generally of short duration; 48% 
resolved within 1 day and 64% in less than 2 days. Most HACs were triggered by 
intercurrent illness and infection and the most commonly reported clinical symptoms 
reported were vomiting (63%) and lethargy (37%) and (48%) (Table S2). Patients with 
baseline ammonia < 1.0 ULN tended to have a higher likelihood of experiencing an HAC of 
less than 2 days duration than patients with baseline ammonia ≥ 1.0 ULN (odds ratio 3.06), 
but this difference was not statistically significant.
Glutamine—Monthly glutamine levels were generally higher in patients in the higher 
baseline ammonia ULN groups and, by three months of treatment, had decreased in the 
patients with the highest baseline glutamine at baseline (Figure 4, top panel). However, there 
was no statistically significant difference between glutamine in patients with or without an 
HAC assessed either at baseline (782.4 vs. 732.0 μmol/L; p = 0.150), during the long term 
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follow up or as total glutamine exposure (TNAUC12month of 720.9 vs. 699.4 μmol/L*m; 
p=0.686).
There were statistically significant but comparatively weak correlations between baseline 
ammonia and glutamine levels at the time of enrollment (r = 0.27; p = 0.008) as well as 
between fasting glutamine levels and daily ammonia exposure on GPB or NaPBA during the 
switchover studies (r = 0.292, p<0.001). However, when the relationship between glutamine 
and ammonia categories with respect to the ULN was analyzed, glutamine values varied 
substantially for patients in each category and the overall correlation appeared to be driven 
by patients whose baseline ammonia exceeded 1.0x ULN (Figure 4). Patients with proximal 
deficiencies (OTC and CPS) showed a stronger correlation between glutamine and ammonia 
(r=0.56; p=0.020; Figure S2). There was no correlation between baseline ammonia and UCD 
subtype or levels of either citrulline (r=0.04; p=0.414) or argininosuccinic acid (r=0.14; 
p=0.158).
DISCUSSION
Twenty-four hour blood sampling in UCD patients demonstrated that blood ammonia levels 
fluctuated considerably over 24 hours, even among the comparatively stable and well-
controlled UCD patients enrolled in these trials, making interpretation of random blood 
ammonia levels difficult. In order to identify the optimal timing of blood draws and a target 
level for ammonia in UCD patients, post-hoc statistical analyses of clinical trial data were 
conducted to assess the short-term relationship between fasting ammonia levels and daily 
ammonia exposure and the long-term relationship between fasting ammonia levels and 
HACs in patients with UCDs.
Analysis of pooled data from the short-term studies showed a strong positive relationship 
between fasting ammonia and ammonia AUC0-24. Because the wide prediction intervals 
observed with this analysis compromised the utility of individual levels for predicting daily 
ammonia exposure, the relationship between fasting ammonia levels categorized in relation 
to the ULN and the likelihood that a patient would have an average or maximal blood 
ammonia within normal limits was modeled using Generalized Estimating Equations. These 
analyses demonstrated that fasting ammonia categorized in relation to the ULN (< 0.5 ULN, 
0.5 to < 1.0 ULN; and ≥ 1.0 ULN) was strongly predictive of the likelihood that maximal 
and mean daily ammonia values would be within normal limits. This finding indicates that 
patients with fasting ammonia outside the normal range are likely being exposed to high 
levels of ammonia during the day, even if they do not exhibit any identifiable symptoms.
In order to further assess the importance of these correlations, data on ammonia, glutamine, 
and HACs collected during the 12-month studies were further analyzed using the patient 
groups by baseline ammonia ULN category. The relationship between baseline ammonia 
ULN category and long-term outcome was demonstrated using several approaches. First, 
monthly ammonia levels continued to be lowest in patients with baseline ammonia levels < 
0.5 ULN and highest in patients with baseline ammonia ≥ 1.0 ULN. Second, the proportion 
of patients experiencing an HAC increased significantly with increasing baseline ammonia 
ULN category. Third, the time to first HAC was significantly shorter and the risk of HAC 
Lee et al. Page 8
Genet Med. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
was significantly greater in patients with baseline ammonia ≥ 1.0 ULN than in those with 
baseline ammonia < 0.5 ULN. This association between baseline ammonia and HAC risk 
was even more apparent when patients less than 6 years of age at baseline (who feed more 
frequently and for whom true fasting ammonia levels are difficult to collect) were excluded 
from the analysis. Finally, the cumulative rate of HAC was more than 5 times higher for 
patients with baseline ammonia ≥ 1.0 ULN than for patients with baseline ammonia < 0.5 
ULN and was 20 times higher when patients less than 6 years of age were excluded.
Just as is true for the relationship between fasting ammonia and daily ammonia exposure, 
the relationship between fasting ammonia and HAC appears to be independent of treatment. 
While fewer crises were experienced by patients during treatment with GPB as compared 
with the prior year on NaPBA, the relationship between ammonia levels and the incidence of 
HACs was similar both prior to enrollment on NaPBA and subsequently during treatment 
with GPB.
The duration of HACs during GPB treatment was generally short, with more than 64% of 
crises lasting less than 2 days. Although ammonia values were generally higher in pediatric 
patients, there were no significant predictors for the admission, peak, or discharge ammonia 
levels during an HAC or for the duration of an HAC.
As compared with ammonia, glutamine appears a weaker predictor of HAC. While 
glutamine levels were higher at baseline in patients who experienced an HAC, there was no 
significant difference in glutamine between patients who did or did not experience an HAC 
during the study and no significant association between the rate of HAC and glutamine 
levels during the 12-months of dosing. Glutamine correlated modestly with fasting ammonia 
at baseline and decreased during GPB treatment in patients with the highest baseline 
glutamine levels. Of interest, the correlation between fasting ammonia and glutamine 
seemed to be primarily driven by patients with the highest ammonia values, a finding similar 
to the report by Maestri14 based on multiple samples in a single OTC patient. In addition, 
the relationship between ammonia and glutamine appeared strongest in patients with the 
proximal UCD subtypes, OTC and CPS (Figure S2), a finding which corroborates an earlier 
report by Wilson.15
Certain limitations of the current analyses deserve emphasis. First, while these timed 
ammonia and glutamine samples were collected prospectively, the analyses are post hoc. 
Second, the fact that lower fasting ammonia levels correlate strongly with lower average 
daily ammonia exposure as well as lower risk and frequency of HAC could reflect intrinsic 
differences in disease severity; i.e., patients with more severely deficient urea synthesis may 
exhibit both higher ammonia levels and increased susceptibility to crises with even minor 
triggering events. Two considerations suggest an alternative explanation. First, baseline 
characteristics including age, gender, and UCD subtype were similar across these ULN 
groups. Second, data pertaining to ammonia levels and the frequency of HAC among 
patients enrolled at 20 sites in North America, even allowing for possible differences in 
compliance among patients at different sites, appear better explained by different responses 
to management or differing management approaches rather than regional differences in 
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severity of illness. In any case, the findings should be interpreted with caution pending 
further study and prospective validation.
The findings suggest that fasting ammonia is a reliable surrogate for assessing adequacy of 
disease control, as it correlates strongly with total daily ammonia exposure as well as HACs. 
They further suggest that even mildly elevated ammonia over long periods of time may put 
patients at risk of HAC and that UCD patients, especially those ages 6 years and above, may 
benefit from maintaining fasting ammonia levels less than 0.5 ULN. More frequent 
monitoring of fasting ammonia levels may require identifying certified clinical laboratories 
conveniently located for patients and/or further development of ‘portable testing’ technology 
analogous to that in use for diabetes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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List of Abbreviations
AUC0-24 daily ammonia exposure assessed as 24 hour area under 
the curve
Cmax maximal daily ammonia concentration
GPB glycerol phenylbutyrate
HAC(s) hyperammonemic crisis (crises)
NaPBA sodium phenylbutyrate
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AUC 0-24 time normalized area under the curve over 24 hours
TNAUC12months time normalized area under the curve for up to 12 
months
UCD urea cycle disorder
ULN upper limit of normal
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Figure 1. 
Correlation of fasting ammonia and daily ammonia exposure in short term crossover studies 
(r = 0.764; p < 0.0001; N = 80). Bolded box indicates normal range. Dashed lines represent 
95% confidence intervals. Dotted boxes indicate fasting ammonia categories. Inset Figure: 
Probability of average daily ammonia being within normal limits by fasting ammonia ULN 
categories.
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Figure 2. 
Ammonia and HAC rate. Top Panel: Mean (± SE) ammonia values during 12 months of 
treatment with GPB by baseline fasting ammonia ULN category. Dotted line indicates upper 
limit of ammonia normal range (35 μmol/L). Bottom panel: Time to first HAC by baseline 
ammonia ULN category for patients at least 6 years old at baseline (P = 0.0077 by log-rank 
test).
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Figure 3. 
Ammonia levels and HAC rate by study site. Top Panel: Percentage of patients at each 
study site with baseline ammonia <0.5 ULN, 0.5 – 1 ULN, and ≥ 1.0 ULN. Bottom Panel: 
Percentage of patients in each ammonia ULN category by sites grouped in relation to 
ammonia levels among patients enrolled at the site. Group 1 (6 study sites; 33 patients, of 
whom >50% had baseline ammonia levels < 0.5 ULN); Group 2 (3 study sites; 29 patients, 
of whom 25%-50% had baseline ammonia levels < 0.5 ULN); and Group 3 (11 sites; 38 
patients, of whom < 25% had baseline ammonia < 0.5 ULN)
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Figure 4. 
Relationship between glutamine and ammonia levels by baseline ammonia categories. Top 
panel: Glutamine levels during 12 months of GBP treatment; mean (± SE) monthly 
glutamine levels by baseline ammonia ULN category. Bottom panel: Scatterplot of baseline 
glutamine by ammonia ULN categories. The overall correlation between glutamine and 
ammonia was significant (r = 0.27; p = 0.008), whereas none of the correlations within 
ammonia ULN categories was significant (r=0.12; 0.18 and 0.12 respectively; p=NS for all)
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Table 1
Patient Characteristics In Relation to Baseline Ammonia Values
Variable Baseline Ammonia Total N = 100
< 0.5 ULN N = 39 0.5 - < 1.0 ULN N = 34 ≥ 1.0 ULN N = 27
Age (years): mean (SD) 22.9 (17.7) 17.4 (15.0) 18.6 (12.8) 19.6 (15.9)
Age Group: N (%) Adult: ≥ 18 22 (56.4) 14 (41.2) 15 (55.6) 51 (51.0)
Pediatric: < 18 17 (43.6) 20 (58.8) 12 (44.4) 49 (49.0)
< 2 3 (7.7) 2 (5.9) 2 (7.4) 7 (7.0)
2 - 5 7 (17.9) 4 (11.8) 5 (18.5) 16 (16.0)
6 - 11 5 (12.8) 10 (29.4) 2 (7.4) 17 (17.0)
12 - 17 2 (5.1) 4 (11.8) 3 (11.1) 9 (9.0)
Gender: N (%) Male 15 (38.5) 9 (26.5) 9 (33.3) 33 (33.0)
Female 24 (61.5) 25 (73.5) 18 (66.7) 67 (67.0)
Fasting Laboratory Values: mean (SD)
    Ammonia (μmol/L) 11 (3.7) 30.8 (7.7) 51.9 (19.5) 28.80 (22.43)
    Glutamine (μmol/L) 694 (199.0) 710 (183.3) 857 (306.0) 743.4 (238.23)
    BUN (mmol/L) 3.4 (1.5) 2.5 (1.0) 2.5 (1.7) 2.8 (1.4)
UCD Subtype: n (%)
    ARG 1 (2.6) 0 (0.0) 1 (3.7) 2 (2.0)
    ASL 7 (18.0) 5 (14.7) 1 (3.7) 13 (13.0)
    ASS 4 (10.3) 3 (8.8) 5 (18.5) 12 (12.0)
    CPS 1 (2.6) 0 (0.0) 0 (0.0) 1 (1.0)
    HHH 2 (5.1) 1 (2.9) 0 (0.0) 3 (3.0)
    OTC 24 (61.5) 25 (73.5) 20 (74.1) 69 (69.0)
12-Month Incidence Rate of HAC
    Pre-enrollment on NaPB A 0.433 0.389 1.071 0.581
    During study on GPB 0.135 0.150 0.711 0.288
ARG: arginase; ASL arginosuccinate lyase; ASS: arginosuccinate synthase; BUN: blood urea nitrogen; CPS: carbonyl phosphate synthetase; HHH: 
hyperornithinemia–hyperammonemia–homocitrullinuria; OTC: ornithine transcarbamylase; UCD: urea cycle disorder; ULN: upper limit of normal; 
HAC: hyperammonemic crisis.
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